Scope and claims breakdown for US Patent 12,201,616 (phentolamine mesylate topical eye drops to reverse mydriasis)
US 12,201,616 claims a post-mydriasis reversal treatment: topical phentolamine mesylate eye drops that are administered after a prior dilating agent (tropicamide and/or phenylephrine) to reduce pupil diameter under photopic conditions within a defined time window, with additional claim limitations on magnitude of miosis, ocular tolerability (redness grades, burning sensation), and accommodation change. The independent claim (claim 1) is anchored on (i) patient selection based on having received tropicamide and/or phenylephrine, (ii) a defined formulation strength and regimen (two drops of a 1% w/w solution), and (iii) a quantitative clinical endpoint (≥30% pupil diameter reduction measured at two hours under photopic conditions). Dependent claims then narrow to particular dilator causes (tropicamide-only, phenylephrine-only, or both), tighter miosis thresholds (≥1 mm, ≥2 mm; and ≥2 mm at two hours), tolerability windows (CCLRU redness change ≤2 grades; no burning), and functional effects (accommodation change), plus operational timing (benefit within 1 hour) and workflow (administer once the patient completes the exam in which the mydriatic was given).
What does US 12,201,616 claim: method scope for reversing tropicamide/phenylephrine mydriasis with topical phentolamine?
Claim 1 is the core scope. It covers a method of treating mydriasis in a human eye where the mydriasis is attributed to prior administration of tropicamide and/or phenylephrine, using topical phentolamine mesylate eye drops with a defined dose and measurable effect at a fixed timepoint.
Claim 1 element-by-element (scope drivers)
-
Patient and indication linkage (eligibility criterion)
- The human patient has mydriasis due to receiving one or more of:
- tropicamide, or
- phenylephrine, or
- pharmaceutically acceptable salts of either.
Practical meaning: the claim is not a “general mydriasis reversal” claim; it is tied to a specific clinical context (post-application of these two common diagnostic/therapeutic dilators).
-
Therapeutic agent
- phentolamine mesylate is administered.
-
Route and dosing form
- Topical administration to the patient’s eye as two eye drops.
-
Formulation strength
- The solution is 1% (w/w) phentolamine mesylate.
-
Timing
- At two hours after administering phentolamine mesylate, the clinical endpoint must be achieved.
-
Quantitative endpoint under defined lighting conditions
- At least a 30% reduction in pupil diameter at two hours.
- Measurement is under photopic conditions.
- Baseline comparison is within the same photopic conditions but “without receiving said dosage” (in claim structure, this functions as a comparator/control concept).
How broad is claim 1 in practice?
- Broad in patient inclusion (any patient with mydriasis caused by these dilators).
- Narrow in product specificity:
- phentolamine mesylate only (not another alpha-blocker),
- 1% w/w solution,
- two drops regimen,
- endpoint requires ≥30% reduction at two hours under photopic conditions.
How do the dependent claims narrow US 12,201,616: tropicamide vs phenylephrine vs combined mydriasis?
Dependent claims 2-4 split by the initiating dilator(s):
Tropicamide-only (claims 2 and 6)
- Claim 2: mydriasis due to receiving tropicamide (or salt).
- Claim 6: adds the magnitude limitation: at least 1 mm reduction under photopic conditions vs no treatment.
Phenylephrine-only (claims 3 and 9)
- Claim 3: mydriasis due to receiving phenylephrine (or salt).
- Claim 9: adds magnitude: at least 2 mm reduction under photopic conditions vs no treatment.
Combined tropicamide + phenylephrine (claim 4)
- Claim 4: mydriasis due to both:
- (a) tropicamide (or salt) and
- (b) phenylephrine (or salt).
This matters for freedom-to-operate: any competitor method must match not just the reversal mechanism, but the cause of mydriasis as framed by the claim.
What miosis magnitude thresholds are protected: ≥30% at 2 hours vs ≥1 mm and ≥2 mm alternatives?
The landscape within claim set defines multiple ways to meet patent-covered efficacy.
Percent-based endpoint
- Claim 1: ≥30% reduction in pupil diameter at two hours, photopic conditions.
Millimeter-based endpoint options (without and with 2-hour timing)
These dependent claims create alternative “covered methods” anchored by measurement units:
- Claim 5: ≥1 mm reduction under photopic conditions (no explicit “two hours” requirement stated in claim 5 text).
- Claim 7: ≥2 mm reduction under photopic conditions.
- Claim 10: at two hours, ≥2 mm reduction under photopic conditions.
- Corresponding variants for tropicamide/phenylephrine-only:
- Claim 6 (tropicamide-only): ≥1 mm reduction
- Claim 8 (tropicamide-only): not provided in your list; only claim 8 exists in numbering as “at least a 2 mm reduction” for claim 2. Your excerpt includes claim 8 implicitly via “method of claim 2 … at least a 2 mm reduction” (present in your text).
- Claim 9 (phenylephrine-only): ≥2 mm reduction
- Claims 11-12: add two-hour timing and photopic mm reductions for respective initiator categories.
Practical implication: A competitor could try to avoid coverage by targeting a different efficacy timepoint, using different measurement conditions, or claiming endpoints that miss the specific magnitude thresholds at specified time windows. The claim set provides multiple “paths” into infringement, but all are measurement- and time-conditioned.
What safety and tolerability endpoints are claimed: redness grade cap, no burning, accommodation change?
The patent set includes tolerability and functional claims that can be used either to strengthen clinical differentiation or to narrow infringement triggers.
Redness grading limitation (CCLRU)
- Claim 13: increase in eye redness of no more than two grades on the CCLRU Redness Grading Scale.
- Claims 14, 15: same redness limitation but tied to dependent claims (claim 7, claim 10).
This can be strategically important: to avoid infringement, a generic competitor could pursue a protocol designed to exceed or alter redness outcomes, but infringement does not typically turn on “how the method was conducted” unless the claim requires the outcome as a condition. Here it does.
No burning sensation limitation
- Claim 16: patient experiences no burning sensation due to the dosage.
This is a subjective endpoint but is still claim-limiting. It can be outcome-sensitive in clinical data.
Accommodation change
- Claim 17: at two hours, accommodation change is ≥ −1 diopters relative to baseline.
This adds a functional ophthalmic effect boundary, potentially differentiating reversal that does not significantly impair accommodation beyond a threshold.
What timing window and clinical benefit kinetics are claimed: benefit within 1 hour?
Timing claims expand beyond the two-hour endpoint:
- Claim 18: “therapeutic benefit observed within 1 hour after administering.”
- Claims 19 and 20: corresponding variants for tropicamide-only and phenylephrine-only (based on the dependent claim references in your excerpt).
This supports earlier efficacy and reduces design-around options based solely on delaying effect.
What workflow/protocol limitation is claimed: administer phentolamine only after completion of the exam?
The method claims include an operational sequence:
- Claim 21: all phentolamine mesylate is administered once the patient has completed an eye examination in which one or more of tropicamide/phenylephrine was administered.
- Claims 22-23: same limitation but tied to dependent claim categories (claim 7, claim 10).
Implication: if a competitor administers phentolamine during an active exam rather than after completion, that could be a factual distinction. Conversely, routine post-exam dosing would fit.
What formulation details are required: aqueous ophthalmic liquid and 1% w/w concentration
- Claim 24: the eye drop is a liquid aqueous ophthalmic formulation.
Together with claim 1’s 1% (w/w) phentolamine mesylate dosing as “two eye drops,” the patent is tightly framed to a specific strength and dosage form category.
What is the likely claim coverage envelope for competitors: designing around dose, timing, and endpoint conditions
Even without additional prosecution history or the full patent specification text, the claim set itself creates a clear “infringement envelope.”
Key infringement must-matches
- Prior dilator cause: tropicamide and/or phenylephrine.
- Agent: phentolamine mesylate.
- Dose: two drops.
- Concentration: 1% (w/w).
- Endpoint: at two hours, ≥30% reduction (claim 1), with alternative dependent endpoints for mm reductions.
- Measurement: photopic conditions.
- Additional outcome constraints for dependent claims:
- redness increase capped at ≤2 grades,
- no burning,
- accommodation change ≥ −1 D.
Primary design-around levers
- Use of a different initiating mydriatic agent outside tropicamide/phenylephrine.
- Different agent (not phentolamine mesylate).
- Different concentration or dosing volume (not two drops of 1% w/w).
- Different timing (avoid reaching claim-specified endpoint at “two hours” or “within 1 hour,” depending on the alleged claim).
- Different measurement conditions (though photopic requirement is explicit in claims).
- Protocol sequencing (administering before exam completion may fall outside claim 21/22/23, if interpreted strictly).
The patent’s structure suggests it is intended to capture a specific clinical reversal practice rather than broad pharmacologic correction.
Patent landscape: what can be concluded from the claim text you provided about enforceable breadth
Only the claims are supplied here, and no expiration date, family members, assignees, continuation status, or litigation record are included in your input. Under strict operating constraints, a full landscape (other patents, expiry, Orange Book listings, Paragraph IV, settlements) cannot be constructed without those missing facts.
What the claims alone indicate about the technical focus
- The claims target a diagnostic/clinical setting: after tropicamide/phenylephrine mydriasis, reverse pupil dilation.
- The claims are built to be trial-measurable: pupil diameter under photopic lighting, mm and % thresholds, redness grading, burning sensation, accommodation diopters.
What that implies for claim strength
- The invention is framed around clinically measurable outcomes that reduce ambiguity in infringement determinations.
- The inclusion of multiple dependent endpoints creates multiple infringement routes if a product performs as measured in trials.
Key Takeaways
- US 12,201,616 claim 1 protects a specific reversal method: two drops of 1% w/w phentolamine mesylate after tropicamide and/or phenylephrine-induced mydriasis, with ≥30% pupil diameter reduction at two hours under photopic conditions.
- Dependent claims narrow by initiating dilator (tropicamide-only, phenylephrine-only, or both) and by efficacy endpoints (≥1 mm or ≥2 mm pupil reduction; some explicitly at two hours).
- The claim set also includes tolerability and functional constraints: redness increase ≤2 CCLRU grades, no burning sensation, and accommodation change ≥ −1 diopters at two hours.
- The method claims include protocol sequencing (administer after completion of the eye exam) and kinetics (therapeutic benefit within one hour).
- Beyond these claim-limited parameters, any competitor method that diverges in agent, strength, dosing, timing, photopic measurement conditions, or outcome thresholds may fall outside the protected scope.
FAQs
1) Does US 12,201,616 cover reversing mydriasis caused by cyclopentolate or other dilators?
No. The patient’s mydriasis must be due to prior administration of tropicamide and/or phenylephrine (claim 1 framework).
2) Is the patent limited to a single timepoint or does it cover earlier effects?
Both. Claim 1 uses a two-hour endpoint, while claims 18-20 cover “therapeutic benefit within 1 hour.”
3) What exact dosing regimen is required by claim 1?
Two eye drops of a 1% (w/w) phentolamine mesylate solution, administered topically to the eye.
4) Are tolerability outcomes required for infringement?
For dependent claims that include those limitations (redness, burning sensation, accommodation change), yes. For claim 1 alone, tolerability limitations are not part of the independent element set you provided.
5) Does the patent require photopic measurement conditions?
Yes. The pupil diameter reductions in the claims you provided are measured under photopic conditions.
References (APA)
- User-provided text: “Detailed analysis of the scope and claims and patent landscape for United States Drug Patent 12,201,616” including the listed claims 1-24 (verbatim excerpt).
